The Federal Trade Commission has approved an amended final order resolving competition concerns with Teva’s proposed acquisition of Cephalon. The approved final order comes after a public consultation. The transaction affects the generics market for three drugs. Teva will have to sell the rights and assets related to a drug used to treat cancer pain (transmucosal fentanyl citrate lozenges) and a generic muscle relaxant (extended release cyclobenzaprine hydrochloride). These two drugs will be sold to Par Pharmaceuticals, Inc. Teva is also required to enter into a supply agreement allowing Par to sell a generic version of Provigil, which is used to treat narcolepsy and other sleep disorders, in 2012.
Full content: FTC Press Release
Related content: Reverse Payment Settlements: Presumptively Bad or Usually Acceptable?
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI